Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on IN8bio (INAB – Research Report) and keeping the price target at $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Swayampakula Ramakanth’s rating is based on several promising developments in IN8bio’s pipeline and financial outlook. The company’s presentation of preclinical data for its INB-600 platform at the AACR meeting highlights its potential to mitigate severe cytokine release syndrome, a significant advantage in treating oncology and autoimmune diseases. This innovation could broaden the platform’s applicability and attract development partners, enhancing its clinical prospects.
Additionally, the upcoming Phase 1 update on INB-200 at the ASCO meeting could further validate its efficacy and safety in treating glioblastoma multiforme, potentially drawing strategic partnerships. Financially, the company reported a net loss in line with expectations and has sufficient cash reserves to fund operations into the second quarter of 2026. These factors, combined with a risk-adjusted net present value analysis, support the Buy rating with a 12-month price target of $6.00 per share.
In another report released on April 28, JonesTrading also maintained a Buy rating on the stock with a $1.20 price target.